Flagship upstart Cellarity gathers $123M to finance its exploration of cell behavior, blazing a new path to building a broad pipeline
Right from the start, the discovery plan at Flagship-spawned Cellarity was to take their cues from cell biology and follow them to new drugs. Rather than start with a target and develop a drug to hit it, they’d use new technology to digitally map cell behavior and then develop new drugs from what they learned.
“Over the past decades it has always been about finding a target, about reducing a disease to a single molecular target,” says Fabrice Chouraqui, the Novartis vet who was recruited to run the operation about 9 months ago. “And that approach has produced thousands of life-saving medicines. Yet, this approach has limitations. A molecular target approach is fine when you talk about a simple disease, but for very complex diseases like neurodegeneration, like metabolic disease, like cancer, you hope to really harness the complexity of human biology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.